Thomas Van Looy

A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal

Giuseppe Floris, Agnieszka Woźniak, Raf Sciot et al. · Clinical Cancer Research · 2012 · 68 citations · Full text

The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models

Tomoko Smyth, Thomas Van Looy, Jayne Curry et al. · Molecular Cancer Therapeutics · 2012 · 59 citations

The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous <i>KIT</i> Mutations

Giuseppe Floris, Raf Sciot, Agnieszka Woźniak et al. · Clinical Cancer Research · 2011 · 49 citations

Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy

Thomas Van Looy, Agnieszka Woźniak, Giuseppe Floris et al. · Clinical Cancer Research · 2014 · 48 citations · Full text

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models

Haifu Li, Agnieszka Woźniak, Raf Sciot et al. · Translational Oncology · 2014 · 42 citations · Full text